Eva Maret

Eva Maret

Auto-generated profile, based on publicly available information

Eva Maret

Department of Clinical Physiology, Karolinska University Hospital, and Karolinska Institutet, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2009 in Cardiovascular Ultrasound
Verified
Journal Article
Open access
PDF file
EMEva Maret
Eva Maret
TTTim Todt
Tim Todt
LBLars Brudin
Lars Brudin
ENEva Nylander
Eva Nylander
ESEva Swahn
Eva Swahn
JEJan Engvall
Jan Engvall
The aim of the study was to perform a feature tracking analysis on cine magnetic resonance (MR) images to elucidate if functional measurements of the motion of the left ventricular wall may detect scar defined with gadolinium enhanced MR.

28 February 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SDSarbashis Das
Sarbashis Das
CFChristoffer Frisk
Christoffer Frisk
MEMaria J. Eriksson
Maria J. Eriksson
AWAnna Walentinsson
Anna Walentinsson
MCMatthias Corbascio
Matthias Corbascio
BPBengt Persson
Bengt Persson
Heart failure affects 2–3% of adult Western population. Prevalence of heart failure with preserved left ventricular (LV) ejection fraction (HFpEF) increases. Studies suggest HFpEF patients to have altered myocardial structure and functional changes such as incomplete relaxation and increased cardiac stiffness. We hypothesised that patients undergoing elective coronary bypass surgery (CABG) with HFpEF characteristics would show distinctive gene expression compared to patients with normal LV physiology. Myocardial biopsies for mRNA expression analysis were obtained from sixteen patients with LV ejection fraction ≥45%. Five out of 16 patients (31%) had echocardiographic characteristics and increased NTproBNP levels indicative of HFpEF and this group was used as HFpEF proxy, while 11 patients had Normal LV physiology. Utilising principal component analysis, the gene expression data clustered into two groups, corresponding to HFpEF proxy and Normal physiology, and 743 differentially expressed genes were identified. The associated top biological functions were cardiac muscle contraction, oxidative phosphorylation, cellular remodelling and matrix organisation. Our results also indicate that upstream regulatory events, including inhibition of transcription factors STAT4, SRF and TP53, and activation of transcription repressors HEY2 and KDM5A, could provide explanatory mechanisms to observed gene expression differences and ultimately cardiac dysfunction in the HFpEF proxy group.

18 February 2016 in Journal of Advanced Nursing
Verified
Journal Article
Open access
PDF file
BABritt‐Marie Ahlander
Britt‐Marie Ahlander
KÅKristofer Årestedt
Kristofer Årestedt
JEJan Engvall
Jan Engvall
EMEva Maret
Eva Maret
EEElisabeth Ericsson
Elisabeth Ericsson
Aim: To develop and validate a new instrument measuring patient anxiety during Magnetic Resonance Imaging examinations, Magnetic Resonance Imaging‐ Anxiety Questionnaire.Background: Questionnaires measuring patients’ anxiety during Magnetic Resonance Imaging examinations have been the same as used in a wide range of conditions. To learn about patients’ experience during examination and to evaluate interventions, a specific questionnaire measuring patient anxiety during Magnetic Resonance Imaging is needed.Design: Psychometric cross‐sectional study with test‐retest design.Methods: A new questionnaire, Magnetic Resonance Imaging‐Anxiety Questionnaire, was designed from patient expressions of anxiety in Magnetic Resonance Imaging‐scanners. The sample was recruited between October 2012–October 2014. Factor structure was evaluated with exploratory factor analysis and internal consistency with Cronbach's alpha. Criterion‐related validity, known‐group validity and test‐retest was calculated.Results: Patients referred for Magnetic Resonance Imaging of either the spine or the heart, were invited to participate. The development and validation of Magnetic Resonance Imaging‐Anxiety Questionnaire resulted in 15 items consisting of two factors. Cronbach's alpha was found to be high. Magnetic Resonance Imaging‐Anxiety Questionnaire correlated higher with instruments measuring anxiety than with depression scales. Known‐group validity demonstrated a higher level of anxiety for patients undergoing Magnetic Resonance Imaging scan of the heart than for those examining the spine. Test‐retest reliability demonstrated acceptable level for the scale.Conclusion: Magnetic Resonance Imaging‐Anxiety Questionnaire bridges a gap among existing questionnaires, making it a simple and useful tool for measuring patient anxiety during Magnetic Resonance Imaging examinations.

17 November 2017 in Journal of Clinical Nursing
Verified
Journal Article
Closed access
PDF file
BABritt-Marie Ahlander
Britt-Marie Ahlander
JEJan Engvall
Jan Engvall
EMEva Maret
Eva Maret
EEElisabeth Ericsson
Elisabeth Ericsson

1 June 2018 in Contemporary Clinical Trials Communications
Verified
Journal Article
Open access
AWAnna Wiik
Anna Wiik
DADaniel P. Andersson
Daniel P. Andersson
TBTorkel B. Brismar
Torkel B. Brismar
SCSetareh Chanpen
Setareh Chanpen
CDCecilia Dhejne
Cecilia Dhejne
TGThomas Gustafsson
Thomas Gustafsson
Although the divergent male and female differentiation depends on key genes, many biological differences seen in men and women are driven by relative differences in estrogen and testosterone levels. Gender dysphoria denotes the distress that gender incongruence with the assigned sex at birth may cause. Gender-affirming treatment includes medical intervention such as inhibition of endogenous sex hormones and subsequent replacement with cross-sex hormones. The aim of this study is to investigate consequences of an altered sex hormone profile on different tissues and metabolic risk factors. By studying subjects undergoing gender-affirming medical intervention with sex hormones, we have the unique opportunity to distinguish between genetic and hormonal effects. The study is a single center observational cohort study conducted in Stockholm, Sweden. The subjects are examined at four time points; before initiation of treatment, after endogenous sex hormone inhibition, and three and eleven months following sex hormone treatment. Examinations include blood samples, skeletal muscle-, adipose- and skin tissue biopsies, arteriography, echocardiography, carotid Doppler examination, whole body MRI, CT of muscle and measurements of muscle strength. The primary outcome measure is transcriptomic and epigenomic changes in skeletal muscle. Secondary outcome measures include transcriptomic and epigenomic changes associated with metabolism in adipose and skin, muscle strength, fat cell size and ability to release fatty acids from adipose tissue, cardiovascular function, and body composition. This study will provide novel information on the role of sex hormone treatment in skeletal muscle, adipose and skin, and its relation to cardiovascular and metabolic disease.

6 March 2015 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Open access
PDF file
PBPeter Blomstrand
Peter Blomstrand
MEMartin Engvall
Martin Engvall
KFKarin Festin
Karin Festin
TLTorbjörn Lindström
Torbjörn Lindström
TLToste Länne
Toste Länne
JEJan Engvall
Jan Engvall
Aims The aim of the study was to determine whether left ventricular systolic function, in terms of global left ventricular longitudinal strain (GLS), and diastolic function, expressed as the ratio between early diastolic transmitral flow and mitral annular motion velocities (E/e′), can predict cardiovascular events in patients with diabetes mellitus type 2. Methods and results We prospectively investigated 406 consecutive patients, aged 55–65 years, with diabetes mellitus, who participated in the CARDIPP study. Echocardiography, pulse pressure (pp), and glycosylated haemoglobin (HbA1c) were analysed. Twelve cases of myocardial infarction and seven cases of stroke were identified during the follow-up period of 67 ± 17 months. Univariate Cox regression analysis showed that E/e′ was a strong predictor of cardiovascular events (hazards ratio 1.12; 95% confidence interval 1.06–1.18, P < 0.001). E/e′ was prospectively associated with cardiovascular events independent of age, sex, GLS, left ventricular ejection fraction (LVEF), pp, and HbA1c in multivariate analysis. Receiver operating characteristic curves showed that E/e′ and HbA1c were the strongest predictors for cardiovascular events, both having an area under the curve (AUC) of 0.71 followed by LVEF with an AUC of 0.65 and GLS of 0.61. In a Kaplan–Meyer analysis, the cumulative probability of an event during the follow-up period was 8.6% for patients with an E/e′ ratio >15 compared with 2.6% for patients with E/e′ ≤15, P = 0.011. Conclusion In middle-aged patients with type 2 diabetes, E/e′ is a strong predictor of myocardial infarction and stroke, comparable with HbA1c and superior to GLS and LVEF.